Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib in acute myeloid leukemia
NCT02343939Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Primary completion
- Sep 2018
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of entospletinib in acute myeloid leukemia (AML) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Dose Limiting Toxicities at 28 days, Morphologic Complete Remission and 2 more. Started Jul 2015; status: terminated.
02
Drugs
entospletinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02343939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343939.